C
Carol L. Gaich
Researcher at Eli Lilly and Company
Publications - 38
Citations - 1718
Carol L. Gaich is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Rheumatoid arthritis & Placebo. The author has an hindex of 15, co-authored 38 publications receiving 1253 citations.
Papers
More filters
Journal ArticleDOI
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor,Edward C. Keystone,Désirée van der Heijde,Michael E. Weinblatt,Liliana del Carmen Morales,Jaime Reyes Gonzaga,Sergey Yakushin,T. Ishii,K. Emoto,Scott Beattie,Vipin Arora,Carol L. Gaich,Terence Rooney,Douglas E Schlichting,William L. Macias,Stephanie de Bono,Yoshiya Tanaka +16 more
TL;DR: In patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab.
Journal ArticleDOI
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Maxime Dougados,Désirée van der Heijde,Ying-Chou Chen,Maria Greenwald,E. Drescher,Jiajun Liu,Scott D. Beattie,Sarah Witt,Inmaculada de la Torre,Carol L. Gaich,Terence Rooney,Douglas E Schlichting,Stephanie de Bono,Paul Emery +13 more
TL;DR: In patients with rheumatoid arthritis and an inadequate response or intolerance to conventional synthetic DMARDs, baricitinib was associated with clinical improvement and inhibition of progression of radiographic joint damage.
Journal ArticleDOI
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
Kim A. Papp,M.A. Menter,M. Raman,D. Disch,Douglas E Schlichting,Carol L. Gaich,William L. Macias,Xiang Zhang,Jonathan Janes +8 more
TL;DR: Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process.
Journal ArticleDOI
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
Josef S Smolen,Joel M. Kremer,Carol L. Gaich,Amy M. DeLozier,Douglas E Schlichting,Li Xie,Ivaylo Stoykov,Terence Rooney,Paul Bird,Juan Sanchez Burson,Mark C. Genovese,Bernard Combe +11 more
TL;DR: Baricitinib improved most PROs through 24 weeks compared with placebo in this study of treatment-refractory patients with previously inadequate responses to bDMARDs, including at least one TNFi.
Journal ArticleDOI
Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis
Alexa B. Kimball,April N. Naegeli,Emily Edson-Heredia,C.-Y. Lin,Carol L. Gaich,Enkeleida Nikaï,Kathleen W. Wyrwich,Gil Yosipovitch +7 more
TL;DR: Itching is a profoundly distressing symptom for many patients with psoriasis, but it has not been rigorously studied using validated tools for this condition.